ASC-话题@MedSci

#ASC#

1352篇内容 | 3988人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1939391, encodeId=7466193939123, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO2022：纳武利尤单抗能显著增加高危肌层浸润性尿路上皮癌患者无病生存时间, objectType=article, longId=728372, objectId=b310e283729d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b310e283729d, replyNumber=0, likeNumber=0, createdTime=2023-02-08, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b310e283729d, moduleTitle=ASCO2022：纳武利尤单抗能显著增加高危肌层浸润性尿路上皮癌患者无病生存时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b310e283729d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939253, encodeId=b4921939253ff, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabeto：2型糖尿病肾病多因素干预对死亡率和MACE的影响, objectType=article, longId=218238, objectId=779121823886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=779121823886, replyNumber=0, likeNumber=114, createdTime=2022-07-13, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=779121823886, moduleTitle=Cardiovasc Diabeto：2型糖尿病肾病多因素干预对死亡率和MACE的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=779121823886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939456, encodeId=5c78193945660, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：在2型糖尿病中，AGEs和可溶性RAGE亚型的循环水平与全因死亡率和心血管并发症的发生有关, objectType=article, longId=731468, objectId=fb5ee3146804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb5ee3146804, replyNumber=0, likeNumber=128, createdTime=2022-11-26, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb5ee3146804, moduleTitle=Cardiovasc Diabetol：在2型糖尿病中，AGEs和可溶性RAGE亚型的循环水平与全因死亡率和心血管并发症的发生有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb5ee3146804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939414, encodeId=6afd193941404, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, objectType=article, longId=728275, objectId=a347e2827567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a347e2827567, replyNumber=0, likeNumber=127, createdTime=2022-06-07, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a347e2827567, moduleTitle=ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a347e2827567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939466, encodeId=212e193946620, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！, objectType=article, longId=734082, objectId=2b97e3408225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b97e3408225, replyNumber=0, likeNumber=84, createdTime=2023-04-29, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b97e3408225, moduleTitle=Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b97e3408225)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939282, encodeId=e6ca1939282e5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, objectType=article, longId=221205, objectId=3c79221205ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c79221205ea, replyNumber=0, likeNumber=65, createdTime=2022-04-26, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c79221205ea, moduleTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c79221205ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939351, encodeId=4dd9193935166, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：睡眠时间可预测糖尿病患者的长期死亡率！, objectType=article, longId=726094, objectId=679de260944d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=679de260944d, replyNumber=0, likeNumber=65, createdTime=2022-06-21, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=679de260944d, moduleTitle=Cardiovasc Diabetol：睡眠时间可预测糖尿病患者的长期死亡率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=679de260944d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939311, encodeId=acb01939311b9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：忽胖忽瘦比一直胖更危害心血管健康！, objectType=article, longId=295138, objectId=6d94295138d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d94295138d9, replyNumber=0, likeNumber=62, createdTime=2022-02-08, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d94295138d9, moduleTitle=Cardiovasc Diabetol：忽胖忽瘦比一直胖更危害心血管健康！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d94295138d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939366, encodeId=dea219393667e, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：动态血压与无症状糖尿病患者心功能障碍的相关性, objectType=article, longId=728164, objectId=7caee28164d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7caee28164d8, replyNumber=0, likeNumber=61, createdTime=2023-04-26, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7caee28164d8, moduleTitle=Cardiovasc Diabetol：动态血压与无症状糖尿病患者心功能障碍的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7caee28164d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939437, encodeId=5e74193943ef8, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：与阿托伐他汀和瑞舒伐他汀相比，匹伐他汀对新发糖尿病的影响, objectType=article, longId=728780, objectId=2ca9e2878050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ca9e2878050, replyNumber=0, likeNumber=81, createdTime=2022-09-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ca9e2878050, moduleTitle=Cardiovasc Diabetol：与阿托伐他汀和瑞舒伐他汀相比，匹伐他汀对新发糖尿病的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ca9e2878050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939276, encodeId=85de19392e6d3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：在2型糖尿病患者中，hs-CRP是心血管事件和全因死亡率的危险因素, objectType=article, longId=220646, objectId=be5c220646c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be5c220646c5, replyNumber=0, likeNumber=67, createdTime=2022-08-15, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be5c220646c5, moduleTitle=Cardiovasc Diabetol：在2型糖尿病患者中，hs-CRP是心血管事件和全因死亡率的危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be5c220646c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939475, encodeId=c37019394e5c3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Front Cardiovasc Med：鳖甲软脉汤通过诱导视网膜血管内皮细胞凋亡抑制糖尿病小鼠视网膜新生血管形成, objectType=article, longId=735824, objectId=344be3582470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=344be3582470, replyNumber=0, likeNumber=78, createdTime=2022-09-21, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=344be3582470, moduleTitle=Front Cardiovasc Med：鳖甲软脉汤通过诱导视网膜血管内皮细胞凋亡抑制糖尿病小鼠视网膜新生血管形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=344be3582470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939377, encodeId=9e1119393e711, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, objectType=article, longId=728406, objectId=362fe28406f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=362fe28406f5, replyNumber=0, likeNumber=103, createdTime=2022-12-11, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=362fe28406f5, moduleTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=362fe28406f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939368, encodeId=3d0a193936868, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, objectType=article, longId=728252, objectId=27bce282523d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27bce282523d, replyNumber=0, likeNumber=85, createdTime=2022-11-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27bce282523d, moduleTitle=2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27bce282523d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939401, encodeId=e037193940111, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量, objectType=article, longId=728268, objectId=918ae28268b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=918ae28268b7, replyNumber=0, likeNumber=92, createdTime=2022-11-22, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=918ae28268b7, moduleTitle=ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=918ae28268b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939344, encodeId=23ef193934497, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：残余脂蛋白胆固醇与肾移植受者移植后新发糖尿病(NODAT)相关, objectType=article, longId=724731, objectId=cdf9e2473153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdf9e2473153, replyNumber=0, likeNumber=81, createdTime=2022-11-18, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdf9e2473153, moduleTitle=Cardiovasc Diabetol：残余脂蛋白胆固醇与肾移植受者移植后新发糖尿病(NODAT)相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdf9e2473153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939326, encodeId=8bf41939326cc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Diabetol：甘油三酯葡萄糖指数与冠心病患者颈动脉斑块的相关性, objectType=article, longId=300712, objectId=9860300e1287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9860300e1287, replyNumber=0, likeNumber=91, createdTime=2023-02-07, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9860300e1287, moduleTitle=Cardiovasc Diabetol：甘油三酯葡萄糖指数与冠心病患者颈动脉斑块的相关性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9860300e1287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939305, encodeId=4e6b1939305a2, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Circulation-Cardiovascular Interventions：冠脉内应用肾上腺素和腺苷对血压正常的急性冠脉综合征患者无复流情况影响的比较（COAR试验）, objectType=article, longId=294311, objectId=d431294311d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d431294311d3, replyNumber=0, likeNumber=90, createdTime=2022-08-09, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d431294311d3, moduleTitle=Circulation-Cardiovascular Interventions：冠脉内应用肾上腺素和腺苷对血压正常的急性冠脉综合征患者无复流情况影响的比较（COAR试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d431294311d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939278, encodeId=8a8f19392e8f5, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, objectType=article, longId=221028, objectId=979e22102878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979e22102878, replyNumber=0, likeNumber=72, createdTime=2022-05-31, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979e22102878, moduleTitle=ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979e22102878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939484, encodeId=4d05193948477, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Front Cardiovasc Med：口服靶向治疗肺动脉高压的效果, objectType=article, longId=736467, objectId=c3f7e3646782, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3f7e3646782, replyNumber=0, likeNumber=84, createdTime=2023-02-09, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3f7e3646782, moduleTitle=Front Cardiovasc Med：口服靶向治疗肺动脉高压的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3f7e3646782)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASC

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO2022：纳武利尤单抗能显著增加高危肌层浸润性尿路上皮癌患者无病生存时间

2023-02-08

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabeto：2型糖尿病肾病多因素干预对死亡率和MACE的影响

2022-07-13

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：在2型糖尿病中，AGEs和可溶性RAGE亚型的循环水平与全因死亡率和心血管并发症的发生有关

2022-11-26

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO：血清IL-8和IL-6水平作为黑色素瘤和NSCLC患者对免疫检查点抑制剂反应的预测因素

2022-06-07

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Lancet：他汀+依折麦布联合治疗vs高强度他汀单药治疗在ASCVD中的疗效更佳！

2023-04-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究

2022-04-26

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：睡眠时间可预测糖尿病患者的长期死亡率！

2022-06-21

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：忽胖忽瘦比一直胖更危害心血管健康！

2022-02-08

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：动态血压与无症状糖尿病患者心功能障碍的相关性

2023-04-26

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：与阿托伐他汀和瑞舒伐他汀相比，匹伐他汀对新发糖尿病的影响

2022-09-24

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：在2型糖尿病患者中，hs-CRP是心血管事件和全因死亡率的危险因素

2022-08-15

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Front Cardiovasc Med：鳖甲软脉汤通过诱导视网膜血管内皮细胞凋亡抑制糖尿病小鼠视网膜新生血管形成

2022-09-21

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究

2022-12-11

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2022 ASCO：PD-L1抑制剂联合EP作为一线疗法对广泛期小细胞肺癌伴有脑转移的的疗效

2022-11-24

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO：适应性体育活动显著改善晚期胰腺癌(APACaP)患者的生活质量

2022-11-22

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：残余脂蛋白胆固醇与肾移植受者移植后新发糖尿病(NODAT)相关

2022-11-18

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Diabetol：甘油三酯葡萄糖指数与冠心病患者颈动脉斑块的相关性

2023-02-07

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Circulation-Cardiovascular Interventions：冠脉内应用肾上腺素和腺苷对血压正常的急性冠脉综合征患者无复流情况影响的比较（COAR试验）

2022-08-09

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO2021:阿特珠单抗+贝伐珠单抗联合治疗对不可切除肝癌有益

2022-05-31

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Front Cardiovasc Med：口服靶向治疗肺动脉高压的效果

2023-02-09

科室
- - 订阅+
  - 更多科室
工具
服务